Mismatch Repair
Mismatch Repair
Treatment Resistant Cancers
Other Unique Bacteria
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Dec 26, 2025

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
Published on: July 28, 2010
Andrea Cercek1, Gustavo Dos Santos Fernandes2, Campbell S Roxburgh3
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Mismatch repair-deficient (dMMR) rectal tumors show resistance to neoadjuvant chemotherapy, with over a fourth progressing. However, these dMMR tumors respond well to chemoradiation, suggesting MMR status is crucial for treatment decisions.
12:45Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: